SEC Tracker
Get the app

Gain Therapeutics GANX

Gain Therapeutics reports Q3 2026 financial results

Gain Therapeutics (GANX) filed an 8-K with the SEC on Nov 10, 2026, 4:07 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. R&D expenses decreased to $1.4M in Q3 2026 from $2.8M in Q3 2025
  2. Net loss was $0.07 per share in Q3 2026 compared to $0.15 per share in Q3 2025
  3. Cash and cash equivalents were $11.7M as of September 30, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Gain Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.